Table 3 Relationship between Ex vivo RSA test results and patients clinical and biologic parameters at enrolment
Count of P. f isolates | Failure of RSA test | In vitro RSA resistance test (RSA > 1%) | Significant in vivo resistance (RSA > 10%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Failure of RSA test | Successful RSA test | p value | Sensitive (RSA survival < 1%) | Resistant (RSA survival ≥ 1%) | p value | Sensitive (RSA survival < 10%) | Resistant (RSA survival ≥ 10%) | p value | |
N = 26 | N = 107 | N = 87 | N = 20 | N = 107 | N = 07 | ||||
mean (N) | mean (N) | mean (N) | mean (N) | mean (N) | mean (N) | ||||
Age | 13.00 (26) | 11.00 (107) | 0.892 | 11.00 (87) | 12.00 (20) | 0.740 | 11.00 (102) | 13.00 (7) | 0.492 |
ParaT0 | 21130 (26) | 24070 (107) | 0.454 | 30795 (87) | 44778 (20) | 0.006 | 22730 (102) | 43900 (7) | 0.076 |
CRP | 96.00 (26) | 44.00 (106) | 0.151 | 42.00 (86) | 67.50 (20) | 0.843 | 41.00 (101) | 96.00 (7) | 0.524 |
GB | 14.77 (25) | 13.94 (100) | 0.410 | 13.80 (80) | 16.19 (20) | 0.110 | 13.90 (95) | 21.80 (7) | 0.118 |
GR | 03.07 (25) | 04.32 (100) | 0.016 | 04.37 (80) | 3.81 (20) | 0.013 | 04.37 (95) | 01.63 (7) | 0.002 |
HB | 08.37 (26) | 10.40 (105) | 0.005 | 10.60 (85) | 10.30 (20) | 0.220 | 10.82 (100) | 05.67 (7) | 0.003 |
PLAQ | 271.1 (25) | 231.0 (100) | 0.541 | 222.5 (80) | 236.0 (20) | 0.403 | 230.0 (95) | 319.0 (7) | 0.314 |
HCT | 28.10 (25) | 37.08 (100) | 0.006 | 37.40 (80) | 35.40 (20) | 0.009 | 37.40 (95) | 14.50 (7) | 0.001 |
BMI | 18.85 (26) | 18.30 (105) | 0.940 | 19.00 (87) | 16.80 (20) | 0.118 | 18.60 (100) | 15.50 (7) | 0.100 |
Temp | 38.45 (26) | 39.10 (107) | 0.060 | 39.10 (87) | 38.40 (20) | 0.076 | 39.10 (100) | 37.90 (7) | 0.064 |